|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
opioid
|
|
gptkbp:approvedInUS
|
1959
|
|
gptkbp:ATCCode
|
N02AA05
|
|
gptkbp:brand
|
gptkb:Numorphan
gptkb:Opana
|
|
gptkbp:CASNumber
|
76-41-5
|
|
gptkbp:chemicalFormula
|
C17H19NO4
|
|
gptkbp:contraindication
|
paralytic ileus
acute or severe bronchial asthma
severe respiratory depression
|
|
gptkbp:developedBy
|
gptkb:Endo_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
1.3–1.7 hours (immediate-release oral)
7–9 hours (extended-release oral)
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstSynthesized
|
1914
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Oxymorphone
|
|
gptkbp:IUPACName
|
gptkb:4,5α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one
|
|
gptkbp:KEGGID
|
D08367
|
|
gptkbp:legalStatus
|
gptkb:Schedule_II_controlled_substance
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
301.34 g/mol
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:PubChem_CID
|
CHEMBL1201207
5284603
DB01192
4447622
|
|
gptkbp:relatedTo
|
gptkb:oxycodone
gptkb:morphine
gptkb:hydromorphone
|
|
gptkbp:riskFactor
|
abuse
overdose
dependence
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
subcutaneous
intravenous
rectal
|
|
gptkbp:sideEffect
|
addiction
nausea
constipation
dizziness
drowsiness
respiratory depression
|
|
gptkbp:UNII
|
9C2M730238
|
|
gptkbp:usedFor
|
pain management
|
|
gptkbp:withdrawnFromMarketUS
|
2017 (Opana ER)
|
|
gptkbp:bfsParent
|
gptkb:Opioids
|
|
gptkbp:bfsLayer
|
7
|